Furthermore, the presence of anti‐RBDs NCL autoantibodies correlates significantly with key clinical indicators like tumour size, stage and growth rate, highlighting their promise as robust biomarkers for tracking prognosis and disease progression in affected individuals45 (Figure 2). Here, NUCLEOLIN is linked to neoplasm.